A Phase 1, Randomized, Open-Label, Trial Evaluating the Plasma, Epithelial Lining Fluid, and Alveolar Macrophage Concentrations of Intravenous Carbavance (RPX2014/RPX7009) in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 08 Sep 2015
Price : $35 *
At a glance
- Drugs Meropenem/vaborbactam (Primary)
- Indications Gram-negative infections
- Focus Pharmacokinetics
- Sponsors Rempex Pharmaceuticals
- 08 Sep 2015 Results published in the Antimicrobial Agents and Chemotherapy.
- 28 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 May 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.